Project Optimus: A Brief Overview & The Impact on Oncology Drug Development

 

Video Summary

In August 2024, the US Food and Drug Administration (FDA) released new guidance for the Project Optimus initiative, titled “Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases”. 9 months on, how has oncology drug development shifted? We have Meredith Manuel, Head of Business Development at Scendea in the hot seat to provide the insight. 


Watch the full interview…

 
Previous
Previous

Development & Regulatory Activities to De-risk & Support Your Fundraising Strategy

Next
Next

UK, EU, & US Regulatory Incentives for Antibiotic Development